Sookoian et al. found that circulating levels of soluble CD40 ligand (sCD40L) was significantly higher in 113 NAFLD patients when compared to 102 control subjects33. This evidence concerns the gene CD40LG and metabolic dysfunction-associated steatotic liver disease.